Get the Stockscreener App
1.30
6.56%
+0.08
Beyond Air Inc stock is currently priced at $1.30, with a 24-hour trading volume of 325.50K.
It has seen a +6.56% increased in the last 24 hours and a -17.72% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.19 pivot point. If it approaches the $1.31 resistance level, significant changes may occur.
Previous Close:
$1.22
Open:
$1.2
24h Volume:
325.50K
Market Cap:
$59.67M
Revenue:
$873.20K
Net Income/Loss:
$-63.23M
P/E Ratio:
-0.6667
EPS:
-1.95
Net Cash Flow:
$-53.56M
1W Performance:
+11.59%
1M Performance:
-17.72%
6M Performance:
-43.23%
1Y Performance:
-78.00%
1D Range:
$1.20
$1.32
52W Range:
$1.06
$6.36
Beyond Air Inc Stock (XAIR) Company Profile
Name
Beyond Air Inc
Sector
Industry
Phone
516 665 8200
Address
825 East Gate Boulevard, Suite 320, Garden City, NY
Beyond Air Inc Stock (XAIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-21 | Initiated | Truist | Buy |
| Oct-22-19 | Initiated | Oppenheimer | Outperform |
Beyond Air Inc Stock (XAIR) Latest News
Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
GlobeNewswire Inc.
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024
GlobeNewswire Inc.
Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast
GlobeNewswire Inc.
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors
GlobeNewswire Inc.
Beyond Air Inc Stock (XAIR) Financials Data
Beyond Air Inc (XAIR) Revenue 2024
XAIR reported a revenue (TTM) of $873.20 thousand for the quarter ending March 31, 2021.
Beyond Air Inc (XAIR) Net Income 2024
XAIR net income (TTM) was -$63.23 million for the quarter ending September 30, 2023, a -24.85% decrease year-over-year.
Beyond Air Inc (XAIR) Cash Flow 2024
XAIR recorded a free cash flow (TTM) of -$53.55 million for the quarter ending September 30, 2023, a -65.57% decrease year-over-year.
Beyond Air Inc (XAIR) Earnings per Share 2024
XAIR earnings per share (TTM) was -$2.06 for the quarter ending September 30, 2023, a -15.08% decline year-over-year.
About Beyond Air Inc
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria.The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.
0.77%
Cap:
|
Volume (24h):